Amneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal

MT Newswires Live04-22

Amneal Pharmaceuticals (AMRX) reported Q1 preliminary adjusted earnings Wednesday of $0.27 per diluted share, up from $0.21 a year earlier.

Analysts polled by FactSet expected $0.17.

Net revenue for the quarter ended March 31 was $722.5 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $719.7 million.

For full-year 2026, the company continues to expect net revenue in the range of $3.05 billion to $3.15 billion. Analysts polled by FactSet expect $3.10 billion.

For 2026, Amneal raised its adjusted diluted EPS outlook to the range of $0.95 to $1.05, compared with the prior estimate of $0.93 to $1.03. Analysts surveyed by FactSet expect $ 0.99.

Additionally, Amneal said it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity payable at closing. The agreement also includes up to $350 million in additional payments tied to regulatory and commercial milestones, and funding of operations through closing.

Shares of Amneal were up more than 3% in Wednesday's pre-bell activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629601738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 18:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629601738","market":"sh","top_or_hot":-1,"title":"Amneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal","media":"MT Newswires Live","content":"<html><body><p> Amneal Pharmaceuticals (AMRX) reported Q1 preliminary adjusted earnings Wednesday of $0.27 per diluted share, up from $0.21 a year earlier.</p><p>Analysts polled by FactSet expected $0.17.</p><p>Net revenue for the quarter ended March 31 was $722.5 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $719.7 million.</p><p>For full-year 2026, the company continues to expect net revenue in the range of $3.05 billion to $3.15 billion. Analysts polled by FactSet expect $3.10 billion.</p><p>For 2026, Amneal raised its adjusted diluted EPS outlook to the range of $0.95 to $1.05, compared with the prior estimate of $0.93 to $1.03. Analysts surveyed by FactSet expect $ 0.99.</p><p>Additionally, Amneal said it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity payable at closing. The agreement also includes up to $350 million in additional payments tied to regulatory and commercial milestones, and funding of operations through closing.</p><p>Shares of Amneal were up more than 3% in Wednesday's pre-bell activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-22 18:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amneal Pharmaceuticals (AMRX) reported Q1 preliminary adjusted earnings Wednesday of $0.27 per diluted share, up from $0.21 a year earlier.</p><p>Analysts polled by FactSet expected $0.17.</p><p>Net revenue for the quarter ended March 31 was $722.5 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $719.7 million.</p><p>For full-year 2026, the company continues to expect net revenue in the range of $3.05 billion to $3.15 billion. Analysts polled by FactSet expect $3.10 billion.</p><p>For 2026, Amneal raised its adjusted diluted EPS outlook to the range of $0.95 to $1.05, compared with the prior estimate of $0.93 to $1.03. Analysts surveyed by FactSet expect $ 0.99.</p><p>Additionally, Amneal said it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity payable at closing. The agreement also includes up to $350 million in additional payments tied to regulatory and commercial milestones, and funding of operations through closing.</p><p>Shares of Amneal were up more than 3% in Wednesday's pre-bell activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629601738","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629601738","pubTimestamp":1776853796,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amneal Pharmaceuticals  reported Q1 preliminary adjusted earnings Wednesday of $0.27 per diluted share, up from $0.21 a year earlier.Analysts polled by FactSet expected $0.17.Net revenue for the quarter ended March 31 was $722.5 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $719.7 million.For full-year 2026, the company continues to expect net revenue in the range of $3.05 billion to $3.15 billion. Analysts polled by FactSet expect $3.10 billion.For 2026, Amneal raised its adjusted diluted EPS outlook to the range of $0.95 to $1.05, compared with the prior estimate of $0.93 to $1.03. Analysts surveyed by FactSet expect $ 0.99.Additionally, Amneal said it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity payable at closing. The agreement also includes up to $350 million in additional payments tied to regulatory and commercial milestones, and funding of operations throu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"Amneal Pharmaceuticals第一季度调整后盈利、收入增长；同意以现金、股票交易方式收购Kashiv BioSciences","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals (AMRX) reported Q1 preliminary adjusted earnings Wednesday of $0.27 per diluted share, up from $0.21 a year earlier.Analysts polled by FactSet expected $0.17.Net revenue for the quarter ended March 31 was $722.5 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $719.7 million.For full-year 2026, the company continues to expect net revenue in the range of $3.05 billion to $3.15 billion. Analysts polled by FactSet expect $3.10 billion.For 2026, Amneal raised its adjusted diluted EPS outlook to the range of $0.95 to $1.05, compared with the prior estimate of $0.93 to $1.03. Analysts surveyed by FactSet expect $ 0.99.Additionally, Amneal said it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity payable at closing. The agreement also includes up to $350 million in additional payments tied to regulatory and commercial milestones, and funding of operations through closing.Shares of Amneal were up more than 3% in Wednesday's pre-bell activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629601738","isCrawlerRequest":true}